Pharmaceutical News

RSS

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

CaPre drug candidate shows promising result on CRP level reduction

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre on C-reactive protein (CRP) levels, a biomarker of CardioVascular Disease risk (CVD) and associated with diabetes and obesity.

3 Sep 2010

New antibacterial peptide effective against infections in burn or blast wounds

An antibacterial peptide developed by Laszlo Otvos, a research professor of biology in Temple's College of Science and Technology, looks to be a highly-effective therapy against infections in burn or blast wounds suffered by soldiers.

2 Sep 2010

Purdue University researchers develop new type of pump for drug-delivery patches

Purdue University researchers have developed a new type of pump for drug-delivery patches that might use arrays of "microneedles" to deliver a wider range of medications than now possible with conventional patches.

2 Sep 2010

SaveRxCanada.com announces enhancement to online shopping system

SaveRxCanada.com, the premier Canadian pharmacy intermediary since 2004, announced an enhancement to its full online shopping system.

2 Sep 2010

iBio and CMB enter development and marketing collaboration with GE Healthcare

iBio, Inc., its development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), and GE Healthcare, a unit of General Electric Company, today announced their entry into an agreement to jointly develop and globally market manufacturing solutions for biopharmaceuticals and vaccines based upon their respective proprietary technologies.

2 Sep 2010

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

Emergent BioSolutions Inc. announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health, for advanced development of the company's third generation anthrax vaccine candidate.

2 Sep 2010

AHF proposes innovative solution to resolve AIDS drug crisis in Florida

As the State of Florida grapples with a budget shortfall that is crippling its AIDS Drug Assistance Program and forcing the state to place more than 1,300 low-income Floridians on waiting lists to access lifesaving AIDS medications, AIDS Healthcare Foundation has proposed an innovative solution to state health officials and seven leading AIDS drug companies that would create a public/private partnership to resolve the drug crisis and get vulnerable Florida AIDS patients on to lifesaving antiretroviral treatment.

2 Sep 2010

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Taking a dietary supplement of organic zinc and the enzyme phytase four days before receiving botulinum toxin injections made the toxin more effective in 93 percent of patients tested in a recent study at The Methodist Hospital in Houston.

2 Sep 2010

Lilly's Evista method patents upheld through March of 2014

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

2 Sep 2010

Researchers develop new technique to trace counterfeit drugs

Counterfeiting of drugs is a huge industry with an annual turnover of more than SEK 500 billion. In Africa the situation is extremely serious. Half of the malaria medication sold there could be ineffective or even harmful. Researchers from Lund and the UK have now developed a technique that could resolve the situation.

2 Sep 2010

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive partnership to develop and commercialize Contrave® (naltrexone SR/bupropion SR), Orexigen's investigational drug for the treatment of obesity, in the United States, Canada and Mexico.

2 Sep 2010

XARELTO achieves net clinical benefit in treatment of patients with DVT

Bayer HealthCare Pharmaceuticals today announced that XARELTO (rivaroxaban), a novel anti-clotting therapy, achieved improvement in net clinical benefit in a study looking at treatment of patients with deep vein thrombosis. DVT is the formation of a blood clot in a deep vein, usually in the legs, that partially or totally blocks the flow of blood.

2 Sep 2010

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

MSD and Cardiome Pharma Corp. today announced that the intravenous (IV) formulation of BRINAVESS™ (vernakalant) has been granted marketing approval in the European Union (EU), Iceland and Norway for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

2 Sep 2010

Biodel replaces Linjeta with trade name VIAject

Biodel Inc. announced today that Linjeta™ (pronounced lin-JET-uh) will replace VIAject as the proposed trade name for Biodel's most advanced product candidate.

2 Sep 2010

QRxPharma announces interim analysis of MoxDuo IR clinical program

QRxPharma announced today a successful interim analysis of its final MoxDuo IR pivotal Phase 3 study required for New Drug Application (NDA) submission.

2 Sep 2010

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Nabi Biopharmaceuticals announced today that it has entered into a long-term commercial manufacturing agreement with Diosynth RTP, Inc. for the manufacture of Drug Substance integral to the production of NicVAX, Nabi's innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse.

2 Sep 2010

Unitract Tuberculin syringe clears FDA 510k market clearance

Unilife Corporation, today announced that its Unitract Tuberculin (TB) Syringe has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).

2 Sep 2010

Involving pharmacists in direct patient care activities has favorable effects: Study

Incorporating pharmacists as members of the health care team in direct patient care roles is a viable solution to help improve U.S. health care, according to the results of a comprehensive, systematic review of the health care literature set to be published in the October 2010 edition of Medical Care.

2 Sep 2010

FDA approves Atomoxetine HCl capsules for ADHD

Actavis has received approval from the U.S. Food & Drug Administration to market Atomoxetine HCl capsules for the treatment of attention deficit/hyperactivity disorder (ADHD).

2 Sep 2010

Pharmaceutical News

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

CaPre drug candidate shows promising result on CRP level reduction

New antibacterial peptide effective against infections in burn or blast wounds

Purdue University researchers develop new type of pump for drug-delivery patches

SaveRxCanada.com announces enhancement to online shopping system

iBio and CMB enter development and marketing collaboration with GE Healthcare

Emergent BioSolutions signs contract with NIAID to develop third generation anthrax vaccine candidate

AHF proposes innovative solution to resolve AIDS drug crisis in Florida

Dietary supplement combining zinc, phytase enhances effectiveness of BTX injections: Study

Lilly's Evista method patents upheld through March of 2014

Researchers develop new technique to trace counterfeit drugs

Orexigen and Takeda partner to develop, commercialize Contrave in US, Canada and Mexico

XARELTO achieves net clinical benefit in treatment of patients with DVT

BRINAVESS IV granted marketing approval in EU for conversion of recent onset AF to sinus rhythm

Biodel replaces Linjeta with trade name VIAject

QRxPharma announces interim analysis of MoxDuo IR clinical program

Nabi Biopharmaceuticals, Diosynth sign long-term commercial manufacturing agreement

Unitract Tuberculin syringe clears FDA 510k market clearance

Involving pharmacists in direct patient care activities has favorable effects: Study

FDA approves Atomoxetine HCl capsules for ADHD

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News